Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient |
|
| Young Kul Jung*, Jong Eun Yeon¢Ó, Jong Hwan Choi¢Ó, Chung Ho Kim¢Ó, Eun Suk Jung¢Ó, Ji Hoon Kim¢Ó, Jong Jae Park¢Ó, Jae Seon Kim¢Ó, Young-Tae Bak¢Ó, and Kwan Soo Byun¢Ó |
| Department of Internal Medicine, *Gachon University of Medicine and Science Gil Medical Center, Incheon, and ¢ÓKorea University College of Medicine, Seoul, Korea |
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| ABSTRACT |
| Adefovir dipivoxil (ADV) is commonly used as an antiviral agent in the treatment of chronic hepatitis B or human immunodeficiency virus infection. Nephrotoxicity has been shown to occur at daily dosages of 60-120 mg. Fanconi's syndrome is a generalized dysfunction of the renal proximal tubular cells, which is usually accompanied by complications. Here we report a case of Fanconi's syndrome in a chronic hepatitis B patient who had been treated with a prolonged regimen of ADV at 10 mg/day. A 47-year-old man complained of severe back and chest-wall pain. He had chronic hepatitis B and had been treated with ADV at a daily dose of 10 mg for 38 months. He was hospitalized because of severe bone pain, and laboratory and radiologic findings suggested a diagnosis of Fanconi's syndrome with osteomalacia. After discontinuation of the ADV, he recovered and was discharged from hospital. His laboratory findings had normalized within 2 weeks. This case indicates that Fanconi's syndrome can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day. Therefore, patients treated with long-term ADV should be checked regularly for the occurrence of ADV-induced Fanconi's syndrome. (Gut Liver 2010;4:389-393) |
| |
| KEYWORD |
| Fanconi syndrome; Adefovir; Chronic hepatitis B |
| |
|
Gut and Liver 2010 Sep; 4(3): 389-393 |
|